

February 3, 2023

To

Listing Department,

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza,

Bandra Kurla Complex, Bandra (E),

MUMBAI -400 051

Company Code No. AUROPHARMA

To

The Corporate Relations Department

BSE LIMITED

Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street,

MUMBAI -400 001

Company Code No. 524804

Dear Sir / Madam,

Sub: Intimation of Record Date pursuant to Regulation 42 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Further to our letter dated January 31, 2023 intimating the date of Board Meeting to be held on February 9, 2023, inter alia, to consider unaudited financial results for the quarter and nine months period ended December 31, 2022 and interim dividend for the FY 2022-23 and pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015, we hereby inform that the interim dividend, if declared, shall be paid to the equity shareholders of the Company whose names appear on the Register of Members as on **February 17, 2023** which is the **Record Date** fixed for this purpose.

Please take the information on record.

Thanking you,

Yours faithfully, For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

(CIN: L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.